Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP12 | P39900 | 7/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GNRHR | P30968 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | MMP8 | P22894 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6882179 | 0.91 | MMP12 (0.57) | MMP12MEN1KMT2AGNRHRMMP13 | |
| SCHEMBL6878595 | 0.89 | MMP12 (0.55) | MMP12MEN1KMT2AGNRHRMAPK14 | |
| SCHEMBL6878598 | 0.89 | MMP12 (0.55) | MMP12MEN1KMT2AGNRHRMAPK14 | |
| SCHEMBL6370857 | 0.86 | MMP12 (0.78) | MMP12MEN1KMT2AGNRHRMMP13 | |
| SCHEMBL6370860 | 0.86 | MMP12 (0.78) | MMP12MEN1KMT2AGNRHRMMP13 | |
| SCHEMBL6455095 | 0.85 | MMP12 (0.71) | MMP12MMP13MMP3MMP9MMP8 | |
| Hydrochloric Acid SCHEMBL6881474 | 0.84 | MMP12 (0.70) | MMP12MMP13MMP3MMP9MMP8 | |
| SCHEMBL8340443 | 0.84 | MMP12 (0.55) | MMP12MMP13MMP3MMP9MMP8 | |
| SCHEMBL6882846 | 0.82 | MEN1 (0.46) | MMP12MEN1KMT2AGNRHRHDAC4 | |
| SCHEMBL6457597 | 0.82 | HDAC4 (0.56) | MMP12MEN1KMT2AMMP13MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | claimed |
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | WARNER-LAMBERT COMPANY LLC | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040072871-A1 | Novel thiophene derivatives, their process of preparation and the pharmaceutical compositions which comprise them | MMP11, MMP13, CBR1 | MMP12 7/4885MEN1 4862/4885KMT2A 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.